Breast cancer screening programmes in selected European countries and Poland
DOI:
https://doi.org/10.12775/34598Keywords
breast neoplasms, mass screening, mammography, public healthAbstract
Breast neoplasms are the most common malignant tumors among women. In recent years breast cancer incidence rate has increased. Due to this fact the European Union presents evidence-based guidelines on breast cancer screening and diagnosis. Recommended and commonly used screening test is mammography. The effectiveness of prophylaxis is measured by a decrease in breast cancer mortality rate. Detailed recommendations in EU member countries differ from those presented by the EU institutions. This paper compares the screening programme in Poland to screening programmes in other EU members. The evaluation considers compliance with European screening guidelines and changes in mortality rates since the introduction of the screening programs. General guidelines in Poland are close to European ones. However, some Polish health centers still use analog mammography instead of recommended digital mammography. Furthermore, mortality rate changes in Poland maintain on a constant level due to women’s reluctant participation in screening tests.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394-424. doi: 10.3322/caac.21492.
Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie. http://onkologia.org.pl/nowotwory-piersi-kobiet/ (dostęp: 25.06.2021).
Jassem J, Kordek R. Onkologia. Podręcznik dla studentów i lekarzy. Gdańsk, Via Medica, 2019.
Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF. Current approaches and challenges in early detection of breast cancer recurrence. J Cancer. 2014 Mar 16; 5(4): 281-90. doi: 10.7150/jca.8016.
Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011 Jan 19; (1): CD001877. doi: 10.1002/14651858.CD001877.pub4.
Sardanelli F, Aase HS, Álvarez M et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. Eur Radiol. 2017 Jul; 27(7): 2737-2743. doi: 10.1007/s00330-016-4612-z.
Lienhard DA. HIP Randomized Breast Cancer Screening Trial (1963–1982). Embryo Project Encyclopedia. http://embryo.asu.edu/handle/10776/12974 (dostęp: 25.06.2021).
Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health. 1989 Jun; 43(2): 107-14. doi: 10.1136/jech.43.2.107.
Peintinger F. National Breast Screening Programs across Europe. Breast Care (Basel). 2019 Dec; 14(6): 354-358. doi: 10.1159/000503715.
Tabár L, Fagerberg CJ, Gad A et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13; 1(8433): 829-32. doi: 10.1016/s0140-6736(85)92204-4.
Hellquist BN, Duffy SW, Abdsaleh S et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011 Feb 15; 117(4): 714-22. doi: 10.1002/cncr.25650.
Schouten LJ, de Rijke JM, Schlangen JT, Verbeek AL. Evaluation of the effect of breast cancer screening by record linkage with the cancer registry, The Netherlands. J Med Screen. 1998; 5(1): 37-41. doi: 10.1136/jms.5.1.37.
Sasieni P. Evaluation of the UK breast screening programmes. Ann Oncol. 2003 Aug; 14(8): 1206-8. doi: 10.1093/annonc/mdg325.
Biesheuvel C, Weigel S, Heindel W. Mammography Screening: Evidence, History and Current Practice in Germany and Other European Countries. Breast Care (Basel). 2011; 6(2): 104-109. doi: 10.1159/000327493.
Boyle P, d'Onofrio A, Maisonneuve P, Severi G, Robertson C, Tubiana M, Veronesi U. Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? Ann Oncol. 2003 Aug; 14(8): 1312-25. doi: 10.1093/annonc/mdg353.
Schünemann HJ, Lerda D, Quinn C et al. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Ann Intern Med. 2020 Jan 7; 172(1): 46-56. doi: 10.7326/M19-2125.
Sardanelli F. Mammografia: aktualizacja zaleceń EUSOBI dotyczących informowania pacjentek. https://www.mp.pl/onkologia/nowotwory/rak-piersi/diagnostyka/196319,mammografia-aktualizacja-rekomendacji-eusobi-dotyczacych-informowania-pacjentek (dostęp: 25.06.2021).
Bojkowski M, Wojnarska A, Koper B. Rola tomosyntezy oraz mammografii spektralnej w diagnostyce kobiet z gęstym utkaniem piersi. [The role of tomosynthesis and spectral mammography in the diagnostic of women with dense breast]. Inżynier i Fizyk Medyczny. 2020; 9(3): 203-206.
Vourtsis A, Berg WA. Breast density implications and supplemental screening. Eur Radiol. 2019 Apr; 29(4): 1762-1777. doi: 10.1007/s00330-018-5668-8.
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016 Sep; 27(suppl 5): v103-v110. doi: 10.1093/annonc/mdw327.
Bobek-Billewicz B, Jurkowski MK. Rola mammografii metodą rezonansu magnetycznego
a. w diagnostyce raka piersi. Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY. 2017; 2(3): 235-242.
Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011 Nov 19; 378(9805): 1804-11. doi: 10.1016/S0140-6736(11)61350-0.
Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019 Mar 22; 11: 2321-2337. doi: 10.2147/CMAR.S189627.
Chiarelli AM, Blackmore KM, Muradali D, Done SJ, Majpruz V, Weerasinghe A, Mirea L, Eisen A, Rabeneck L, Warner E. Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program. J Natl Cancer Inst. 2020 Feb 1; 112(2): 136-144. doi: 10.1093/jnci/djz079.
Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S. Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer. Radiology. 2017 May; 283(2): 361-370. doi: 10.1148/radiol.2016161444.
Mango VL, Goel A, Mema E, Kwak E, Ha R. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis. J Magn Reson Imaging. 2019 Jun; 49(7): e216-e221. doi: 10.1002/jmri.26334.
Basu P, Ponti A, Anttila A et al. Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report. Int J Cancer. 2018 Jan 1; 142(1): 44-56. doi: 10.1002/ijc.31043.
Ebell MH, Thai TN, Royalty KJ. Cancer screening recommendations: an international comparison of high income countries. Public Health Rev. 2018 Mar 2; 39: 7. doi: 10.1186/s40985-018-0080-0.
Narodowy Fundusz Zdrowia. Programy profilaktyczne. https://www.nfz.gov.pl/dla-pacjenta/programy-profilaktyczne/ (dostęp: 25.06.2021).
De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014 Jan; 15(1): 23-34. doi: 10.1016/S1470-2045(13)70546-1.
Sant M, Allemani C, Santaquilani M et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009 Apr; 45(6): 931-91. doi: 10.1016/j.ejca.2008.11.018.
Woźniacki P, Skokowski J, Bartoszek K, Kosowska A, Kalinowski L, Jaśkiewicz J. The impact of the Polish mass breast cancer screening program on prognosis in the Pomeranian Province. Arch Med Sci. 2017 Mar 1; 13(2): 441-447. doi: 10.5114/aoms.2016.60387.
Narodowy Fundusz Zdrowia. Objęcie populacji programem profilaktyki raka piersi - podział na gminy (2021-06-01). https://www.nfz.gov.pl/dla-pacjenta/programy-profilaktyczne/dane-o-realizacji-programow/ (dostęp: 25.06.2021).
Lechowicz-Dyl K. Mammobusy wznowiły funkcjonowanie. https://www.mp.pl/pacjent/onkologia/aktualnosci/240205,mammobusy-wznowily-funkcjonowanie (dostęp: 25.06.2021).
Dyzmann-Sroka A, Trojanowski M. Dlaczego polki nie robią badań profilaktycznych? Nowiny Lekarskie. 2012; 81(3): 258–264.
Robb K, Wardle J, Stubbings S et al. Ethnic disparities in knowledge of cancer screening programmes in the UK. J Med Screen. 2010; 17(3): 125-31. doi: 10.1258/jms.2010.009112.
Lagerlund M, Hedin A, Sparén P, Thurfjell E, Lambe M. Attitudes, beliefs, and knowledge as predictors of nonattendance in a Swedish population-based mammography screening program. Prev Med. 2000 Oct; 31(4): 417-28. doi: 10.1006/pmed.2000.0723.
Bogus R, Charzyńska-Gula M, Majewska A, Gałęziowska E. Wiedza kobiet w wieku okołomenopauzalnym na temat profilaktyki raka piersi. Medycyna Ogólna i Nauki o Zdrowiu. 2013; 19(4): 523-529.
Ślusarska B, Nowicki GJ, Łachowska E et al. Wiedza kobiet na temat profilaktyki raka piersi w wybranych uwarunkowaniach socjo-demograficznych. Medycyna Ogólna i Nauki o Zdrowiu. 2016; 22(1): 59-65. doi: 10.5604/20834543.1198725.
Krajewska-Kułak E, Najdyhor E, Krajewska-Ferishah K. Knowledge of women and men about breast cancer prevention. Ginekol Pol. 2013; 84: 116-125. DOI: 10.17772/gp/1551
Koczkodaj P, Sulkowska U, Gotlib J, Mańczuk M. Breast cancer mortality trends in Europe among women in perimenopausal and postmenopausal age (45+). Arch Med Sci. 2019 Jul 11; 16(1): 146-156. doi: 10.5114/aoms.2019.85198.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1277
Number of citations: 0